A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
A phase 2 trial of Infigratinib in Glioma & glioblastoma, run by Novartis Pharmaceuticals, completed.
Overview
A Phase 2 Study of BGJ398 in Patients With Recurrent GBM is a phase 2 interventional study registered as NCT01975701 by Novartis Pharmaceuticals, with 26 participants recorded, started 2013-12-09 and reaching its primary completion in 2018-10-03. Interventions recorded: BGJ398. Conditions recorded: Recurrent Glioblastoma or Other Glioma Subtypes.
Linked to the drug Infigratinib because the registry names it among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialBGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
Shares Infigratinib and the tag pipeline.
- TrialLGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Shares Infigratinib and the tag pipeline.
- TrialInjection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Shares Glioma & glioblastoma and the tag pipeline.